Vardenafil (Levitra/Staxyn) Cost in New Jersey: 2026 Pricing, Insurance, and Savings Guide

What Vardenafil Actually Costs at New Jersey Pharmacies in 2026

The average cash price for generic vardenafil at New Jersey retail pharmacies in 2026 sits near $120 per month for a standard supply of on-demand dosing. Brand-name Levitra carries a manufacturer list price around $350 per month, though few patients pay full list price after discounts and insurance adjustments. Staxyn (the orally disintegrating tablet formulation) is priced slightly higher than standard Levitra tablets in most NJ markets.

Prices vary across the state. Large chain pharmacies like CVS, Walgreens, and Rite Aid in northern New Jersey metro areas (Newark, Jersey City, Hoboken) tend to price within $5 to $15 of each other for generic vardenafil. Independent pharmacies in southern New Jersey, particularly in Camden and Atlantic counties, sometimes undercut chains by 10 to 20 percent. Costco pharmacies in Edison and Cherry Hill have historically offered some of the lowest per-tablet pricing in the state, and membership is not required for pharmacy purchases under New Jersey law.

Vardenafil earned FDA approval in 2003 as a PDE5 inhibitor for erectile dysfunction after the key trial by Porst et al. (2003) demonstrated statistically significant improvements in erectile function scores compared to placebo across multiple fixed-dose groups. That trial enrolled 580 men and found that 20 mg vardenafil improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 9.9 points versus 3.7 points for placebo (P<0.001) [1]. The generic versions available today contain the same active molecule with identical bioequivalence standards enforced by the FDA's Office of Generic Drugs.

New Jersey Medicaid Coverage for Vardenafil

New Jersey Medicaid does cover vardenafil, but a prior authorization (PA) is required before the state will reimburse. The PA process requires the prescribing clinician to document a diagnosis of erectile dysfunction and confirm that the medication is medically necessary. This is consistent with the broader pattern across state Medicaid programs, where ED medications are categorizable as optional benefits under federal Medicaid rules but individual states retain authority over formulary placement and utilization controls [2].

For NJ FamilyCare (the state's Medicaid managed care program), the PA turnaround is typically 24 to 72 hours. Denials can be appealed through the managed care organization's standard grievance process. Patients enrolled in Medicaid fee-for-service may experience slightly different turnaround times. New Jersey does not impose a hard quantity limit on vardenafil tablets per month in its published preferred drug list, but most managed care organizations cap dispensing at 6 to 8 tablets per 30-day fill.

According to a 2020 analysis published in the Journal of Sexual Medicine, Medicaid programs that require prior authorization for PDE5 inhibitors see 15 to 30 percent lower utilization rates compared to programs with open access, raising questions about whether administrative barriers reduce appropriate use alongside inappropriate use [3]. New Jersey's approach falls in the middle of state-level strictness: the state covers the drug but gates access with PA, unlike a handful of states that exclude PDE5 inhibitors from Medicaid entirely.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a contributor to the American Urological Association's ED guidelines, has stated: "PDE5 inhibitors remain first-line pharmacotherapy for erectile dysfunction, and insurance coverage barriers can delay treatment in a condition that significantly impacts quality of life" [4].

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for vardenafil in New Jersey is inconsistent. Large employers and state employee plans often include generic vardenafil on Tier 2 or Tier 3 of their formularies with copays ranging from $20 to $75 per fill. Some plans exclude ED medications entirely.

Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, covers generic vardenafil on many of its commercial plans but typically requires step therapy or PA. Aetna and UnitedHealthcare plans sold in the NJ marketplace vary by specific product; some include generic PDE5 inhibitors while others classify them as lifestyle medications and exclude coverage.

Medicare Part D plans in New Jersey do not cover vardenafil. The Medicare Modernization Act of 2003 specifically excluded ED medications from Part D formularies, and that exclusion remains in effect as of 2026. This means New Jersey Medicare beneficiaries pay cash or use discount programs. A 2017 study in JAMA Internal Medicine found that Medicare's ED drug exclusion disproportionately affects men over 65 with comorbid cardiovascular disease and diabetes, populations where ED prevalence exceeds 50 percent [5].

For patients with no coverage or excluded plans, the out-of-pocket math is straightforward. At $120 per month for generic vardenafil, annual spending reaches roughly $1,440. Using manufacturer discount cards or pharmacy coupons can reduce this by 20 to 40 percent in many cases, bringing the effective annual cost closer to $860 to $1,150.

Compounded Vardenafil in New Jersey

Compounded vardenafil is available in New Jersey through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and can prepare vardenafil in custom formulations (sublingual troches, combination tablets with other agents) when a licensed prescriber writes a patient-specific prescription.

New Jersey regulates compounding pharmacies under N.J.A.C. 13:39, which aligns with FDA guidance under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy may compound vardenafil for an individual patient with a valid prescription, provided the compounded product is not essentially a copy of a commercially available drug. In practice, compounding pharmacies often combine vardenafil with other active ingredients (such as tadalafil or oxytocin) to differentiate the formulation from the commercial product and satisfy the regulatory requirement.

The FDA's compounding guidance clarifies the distinction between 503A (patient-specific) and 503B (outsourcing facility) compounding [6]. New Jersey patients should verify that any compounding pharmacy they use holds a current NJ Board of Pharmacy license and compounds under 503A or 503B authority. Pricing from 503A pharmacies is highly variable but can undercut retail generic pricing, particularly for combination formulations.

A key consideration: compounded drugs are not FDA-approved products. They do not undergo the same bioequivalence testing as generic medications. The National Academies of Sciences report on compounding has noted that quality assurance in compounding pharmacies varies, and patients should choose pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) when possible [7].

Telehealth Prescribing of Vardenafil in New Jersey

Telehealth prescribing of vardenafil is legal and widely practiced in New Jersey. The state's telehealth parity law, updated during the COVID-19 era and made permanent by Governor Murphy's signing of S.B. 2559 in 2024, requires insurers to cover telehealth visits at the same rate as in-person visits.

Multiple telehealth platforms, including HealthRX, operate in New Jersey and can prescribe vardenafil after a virtual evaluation. The prescribing clinician must hold an active New Jersey medical license (or practice under a qualifying interstate compact). Prescriptions can be sent electronically to any licensed New Jersey pharmacy, including compounding pharmacies.

Telehealth has measurably expanded access to ED treatment. A 2021 cross-sectional study found that telehealth visits for ED increased by over 300 percent between 2019 and 2021, with the majority of visits resulting in a PDE5 inhibitor prescription [8]. For New Jersey patients in rural southern counties (Salem, Cumberland, Cape May) where urologists are scarce, telehealth eliminates the 45- to 90-minute drive to the nearest specialist.

The standard telehealth workflow for vardenafil in New Jersey involves completing a health questionnaire, a synchronous video or audio visit with a licensed provider, and electronic prescription routing. Most platforms can complete this process within 24 to 48 hours. Patients with contraindications to PDE5 inhibitors (concurrent nitrate therapy, recent stroke or MI within 6 months, severe hepatic impairment) will be identified during screening and referred for in-person evaluation.

How Vardenafil Compares to Other PDE5 Inhibitors on Cost in NJ

Vardenafil sits in the middle of the PDE5 inhibitor price range in New Jersey. Generic sildenafil (Viagra) is the cheapest option, averaging $15 to $40 per month at NJ pharmacies. Generic tadalafil (Cialis) runs $30 to $80 per month for on-demand dosing or daily 5 mg use. Generic vardenafil at $120 per month is more expensive than both.

The price difference raises an obvious question: why choose vardenafil? The clinical answer lies in its pharmacokinetic profile. Vardenafil has a relatively selective binding affinity for PDE5 compared to sildenafil, with a 10-fold higher selectivity over PDE6 (the retinal enzyme responsible for visual disturbances reported with sildenafil) [9]. For patients who experience blue-tinted vision or visual changes on sildenafil, vardenafil may produce fewer visual side effects.

The onset of action for vardenafil is 30 to 60 minutes, similar to sildenafil. Duration of effect is roughly 4 to 5 hours, shorter than tadalafil's 36-hour window but comparable to sildenafil's 4- to 6-hour range. Staxyn (vardenafil ODT) dissolves on the tongue without water, which some patients prefer for convenience or discretion.

Dr. Irwin Goldstein, Director of San Diego Sexual Medicine, has noted: "PDE5 inhibitor selection should be individualized based on patient preference, side-effect profile, and pharmacokinetics rather than defaulting to the least expensive option" [10]. For NJ patients where cost is the primary driver, sildenafil or tadalafil may be the better fit. For patients who have tried those agents and experienced side effects or inadequate response, vardenafil represents a clinically reasonable alternative.

Discount Programs and Savings Strategies for NJ Patients

Several discount pathways can reduce vardenafil costs for New Jersey residents. The most commonly used options include pharmacy discount cards (GoodRx, RxSaver, SingleCare), manufacturer savings programs, and patient assistance programs.

GoodRx and similar aggregators consistently show generic vardenafil prices in the $40 to $90 range at New Jersey pharmacies when using their free coupons. This represents a 25 to 65 percent discount off the average $120 cash price. Prices fluctuate monthly as pharmacy purchasing contracts change, so checking multiple aggregators before each fill is advisable.

Bayer's branded savings card for Levitra has limited utility in 2026 since most prescriptions are filled with generics. However, for patients whose prescribers write "brand medically necessary" (DAW-1), the Bayer card can reduce brand Levitra copays. The card is not valid for government-insured patients (Medicaid, Medicare, Tricare).

For uninsured or underinsured New Jersey patients, the NeedyMeds database catalogs patient assistance programs that may cover PDE5 inhibitors. Some generic manufacturers offer their own PAPs, though availability changes year to year. New Jersey's Pharmaceutical Assistance to the Aged and Disabled (PAAD) program provides prescription assistance to qualifying residents aged 65 and older, but ED medications are typically excluded from the PAAD formulary.

A practical strategy for cost-conscious NJ patients: request a prescription for 20 mg tablets and use a pill splitter to create two 10 mg doses. This effectively halves the per-dose cost. The Porst et al. trial used 5, 10, and 20 mg fixed doses and found efficacy at all three levels, supporting the clinical rationale for dose adjustment [1]. Confirm this approach with your prescriber before splitting tablets, as Staxyn (ODT) tablets cannot be split.

Safety Considerations and Prescribing Context

Vardenafil carries the same FDA black-box warning as other PDE5 inhibitors regarding concurrent use with nitrates [11]. The combination can produce severe, potentially fatal hypotension. This applies to all nitrate formulations: nitroglycerin (sublingual, patch, spray), isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite ("poppers").

Vardenafil also has a unique QTc prolongation warning not shared by sildenafil or tadalafil. A 2005 study by Morganroth et al. found that vardenafil 80 mg (four times the maximum recommended dose) increased QTc by approximately 10 milliseconds [12]. At the standard 10 to 20 mg dose, QTc effects are minimal, but the labeling advises caution in patients with congenital QT prolongation, those taking Class IA or Class III antiarrhythmics, or those with multiple risk factors for torsades de pointes.

New Jersey prescribers should screen for these contraindications during initial evaluation, whether in-person or via telehealth. An AUA guideline update (2018) recommends that PDE5 inhibitor prescribing include cardiovascular risk assessment, medication reconciliation for nitrate and alpha-blocker interactions, and hepatic function evaluation [4]. Vardenafil dose adjustment is required for moderate hepatic impairment (Child-Pugh B): the starting dose should not exceed 5 mg.

Patients filling vardenafil at New Jersey pharmacies should receive counseling on timing (take 30 to 60 minutes before anticipated sexual activity), food interactions (high-fat meals delay absorption by approximately 60 minutes for standard tablets but not for Staxyn ODT), and alcohol (moderate alcohol does not significantly alter vardenafil pharmacokinetics, but excessive alcohol can worsen ED independently).